Kaye Foster's most recent trade in Prime Medicine Inc was a trade of 45,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Aug. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Kaye Foster | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Aug 2025 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 39,062 | 39,062 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Kaye Foster | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Aug 2025 | 39,062 | 0 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Kaye Foster | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Aug 2025 | 13,510 | 0 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 13,510 | 13,510 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 9,006 | 9,006 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | Kaye Foster | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Aug 2025 | 9,006 | 0 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 7,468 (0%) | 0% | 0 | Common stock | |
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2024 | 3,564 | 5,348 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 8,912 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 31.62 per share. | 07 Mar 2024 | 1,285 | 5,524 (0%) | 0% | 31.6 | 40,632 | Common stock |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 31.99 per share. | 05 Mar 2024 | 4,415 | 6,809 (0%) | 0% | 32.0 | 141,236 | Common stock |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 32.21 per share. | 05 Mar 2024 | 300 | 11,224 (0%) | 0% | 32.2 | 9,663 | Common stock |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 25.96 per share. | 09 Aug 2023 | 25,000 | 11,524 (0%) | 0% | 26.0 | 648,888 | Common stock |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 25,000 | 4,307 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 09 Aug 2023 | 25,000 | 36,524 (0%) | 0% | 18.1 | 452,250 | Common stock |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 11,524 (0%) | 0% | 0 | Common stock | |
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 39,062 | 39,062 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jan 2023 | 2,200 | 6,549 (0%) | 0% | 0 | Common stock | |
| Prime Medicine Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2022 | 9,006 | 9,006 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 8,749 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Kaye I. Foster-Cheek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 7,164 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Kaye I. Foster-Cheek | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Kaye I. Foster-Cheek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Kaye I. Foster-Cheek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit |